For most organisations, data has become their most important strategic asset, and here at Interface we’re no exception. Extensive data analysis is carried out on all our clinical services, to ensure we’re continually delivering the highest value for our clients and identifying opportunities to deliver further value.
Interface work closely with our clients to develop bespoke dashboards that produce real life data intelligence, which is integral to any organisations' continual progression. Whether it’s prescribing data, sales insight and budget impact data or even intelligence on competitors, the data Interface provide will assist with the monitoring, evaluation and achievement of key targets and milestones.
It is increasingly recognised that pharma organisations can take huge learnings from real life, evidence-based data to support organisational objectives and gain improved insight into clinical outcomes.
This is in direct response to the limitations of data produced during trials, conducted under controlled conditions, for a limited time, on a small number of patients. Whilst necessary for achieving product marketing authorisation, these trials are detached from the reality of the general population with all the real-world issues of age, gender, ethnicity, comorbidities and side-effects that influence the true effect of a drug on its patient population.
Increasingly pharma companies are looking for evidence gleaned from clinical databases and grounded in real-world evidence that allow them to demonstrate value and strengthen their product’s placing within national guidance.
At interface we can use our unequalled experience and understanding of electronic medical records to build economic and clinical models that enhance product positioning. This increases the opportunities for market access into a cash and capacity restrained healthcare system.